Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
In connection with the closing of the Share Purchase Agreement, the Company and GPCR entered into a License and Collaboration Agreement (“L&C Agreement”) to further develop and commercialize GPCR’s technologies related to certain intellectual property and patents. The L&C Agreement requires the Company to make milestone payments to GPCR upon the achievement of specific milestone events relating to clinical trials, marketing authorizations, and net sales, as well as for the Company to pay a recurring royalty payment based on at least
About GPCR
GPCR
GPCR
In December of last year, GPCR
Currently, the ongoing clinical trials have met all primary evaluation indicators and are at the stage of deciding whether to proceed to Phase 3. Dr. Caderelli proposed a double-blind clinical trial comparing the mobilization agent Plerixafor with GPC-100. Research has shown that the combination of GPC-100 and propranolol increases the number of specific T cells, which are favorable for enhancing CAR-T (Chimeric Antigen Receptor T-cell) response rates, and relevant papers are being published. Thus, this could assist Exicure in expanding its additional pipeline for cell and gene therapies.
Dr. Caderelli suggested that in the future, it will be essential to prioritize discussions with various partners based on the likelihood of success and high return on investment. She mentioned, "We are also researching interesting hypotheses, such as obesity treatments."
She concluded, "If the hypotheses presented to GPCR
In 2019, Dr. Caderelli became interested in the CXCR4 antibody Ulocuplumab and initially joined a project at GPCR
About Exicure, Inc.
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. There can be no assurance regarding our ability to comply with the Panel’s decision and the applicable listing criteria by the deadline or thereafter. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual outcomes to differ materially from the outcomes expressed or implied by this report. Such risks include, among others, the possibility we will not be able to cure existing listing deficiencies, the possibility of additional deficiencies, the risk that the Company may not adequately comply with the terms of the Panel’s decision, and the risk that Nasdaq will ultimately delist the Company’s common stock. All such factors are difficult to predict and may be beyond the Company’s control. The Company undertakes no obligation and does not intend to update or revise any forward-looking statements contained herein, except as required by law or regulation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122516457/en/
Media Contact:
Josh Miller
847-673-1700
media@exicuretx.com
Source: Exicure, Inc.